Clinical trial Recruiting at 1 site Interventional Ages 30 to 75

How people with Parkinson's disease perceive social cues

Official title: Social Perception and Dopaminergic Modulation in Patients With Parkinson's Disease: a Functional MRI Study (Park Social-E-Motion)

Run by Hospices Civils de Lyon · NCT06884722 · Data updated 2026-11-12

This trial tries to see if dopaminergic medication changes brain activity during social perception tasks in people with Parkinson's disease using a behavioral point-light display task and 3T fMRI.

Quick facts

Study typeInterventional
Ages30 Years to 75 Years
SexAll
Enrollment83 (estimated)
SponsorHospices Civils de Lyon
Academic / other
Locations1 site (Bron)
StatusRecruiting
StartedJuly 15, 2025
Main results expectedApril 2027
Study endsApril 2027
Registry record updatedJuly 22, 2025
Trial IDNCT06884722 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are men or women age 30–75 with a Parkinson's diagnosis for at least three years who are on dopaminergic treatment, have MoCA ≥ 26, can give informed consent, and can attend imaging visits including standard dopa testing.

Probably not a fit

People with disabling chronic diseases, significant cognitive impairment (MoCA < 26), contraindications to MRI, or who are not receiving dopaminergic therapy are unlikely to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study enrolls people with Parkinson's disease who have been on dopaminergic treatment for at least three years and who have preserved global cognition. Participants complete a behavioral task using point-light displays of social interactions and undergo 3 Tesla functional MRI to map networks involved in movement perception, action observation, and mentalizing. The protocol includes neurological and neuropsychological assessments and examines the effect of dopaminergic modulation on those networks (for the imaging stage). Data will be used to relate task performance to activity in motor, parietal, and superior temporal sulcus regions implicated in social cognition.

Why it matters

Potential benefit: If successful, this could clarify why social perception is impaired in Parkinson's and guide medication or behavioural approaches to improve social functioning and relationships.

How similar studies have gone: Previous research has demonstrated altered social cognition and related brain activation in Parkinson's disease, but using point-light displays with dopaminergic modulation and 3T fMRI is a relatively novel combination.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Male or female between 30 and 75 years of age
* Freely-given informed consent to participate to this study (written form)
* Affiliated with a social security system or equivalent;
* Person diagnosed with Parkinson's disease according to MDS-UPDRS criteria for at least 3 years and receiving dopaminergic treatment (e.g. : LEVODOPA, CARBIDOPA, BENZERASIDE, ENTACAPONE, MODOPAR, SINEMET, STALEVO, PRAMIPEXOLE, SIFROL, ROPINIROLE, REQUIP ; ROTIGOTINE, NEUPRO, PIRIBEDIL, TRIVASTAL, RASAGILINE, AZILECT, CONTAM, AMANTADINE, MANTADIX, APOMORPHINE, APOKINON, DOPACEPTIN, FOSLEVODOPA, FOSCARBIDOPA, SCYOVA) (for patients only)
* Effective contraception for women of childbearing age or post-menopausal women (only for patients and healthy volunteers in stage 2 "imaging")
* Requiring dopa testing as part of routine care (only for patients in stage 2 "imaging")
* No disabling cognitive impairment (MOCA score ≥ 26)
* No diagnosis of chronic disease associated with disability (only for healthy volunteers)

Exclusion Criteria:

* Contraindication to MRI (only for patients and healthy volunteers in step 2 "imaging"):

  * Wearing a pacemaker not approved for 3 Tesla MRI
  * Presence of intracerebral ferromagnetic or magnetizable material
  * Presence of intraocular ferromagnetic or magnetizable foreign bodies
  * Presence of non-removable ferro-magnetic or magnetizable foreign bodies in the cephalic region
  * Claustrophobia
* History of head trauma with loss of consciousness lasting more than 30 min (only for patients and healthy volunteers in step 2 "imaging")
* Participant not agreeing to be informed in the event of incidental discovery of an abnormality on MRI (only for patients and healthy volunteers in stage 2 "imaging")
* Tremor or disabling dyskinesias preventing MRI (only for patients in stage 2)
* Having exceeded the annual amount of compensation allowed for participation in research protocols (only for healthy volunteers)
* Pregnant, parturient or breast-feeding women
* Persons deprived of liberty by judicial or administrative decision
* Persons under psychiatric care
* Persons admitted to a health or social institution for purposes other than research
* Adults under legal protection (guardianship, curatorship)
* Participants in other intervention research involving a period of exclusion still in progress at the time of pre-inclusion.

Where it's running

  • Service de neurologie - troubles du mouvement et pathologies neuromusculaires, Hôpital neurologique Pierre Wertheimer/GHE
    Bron, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.